0.0004  0 (0%)		11-12 16:00
Open: 0.0005 High: 0.0005 Volume: 133		Pre. Close: 0.0004 Low: 0.0004 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0	1-year :	0
Resists	First :	0	Second :	0
Pivot price	0
Supports	First :	0	Second :	0
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	33.3
RSI	RSI(14): 40.1
52-week	High :	0.03	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EVLO ] has closed above bottom band by 0.0%. Bollinger Bands are 16% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0 - 0	0 - 0
Low:	0 - 0	0 - 0
Close:	0 - 0	0 - 0

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Thu, 13 Nov 2025
Traders Buy High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO) - Defense World

Wed, 22 Nov 2023
Flagship-backed microbiome biotech Evelo to shut down - BioPharma Dive

Thu, 27 Apr 2023
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today? - InvestorPlace

Wed, 29 Mar 2023
5 Best Microbiome Companies (November 2025) - Securities.io

Wed, 01 Feb 2023
Flagship-backed biotech cuts nearly half its staff - The Business Journals

Tue, 07 Jun 2022
Cytovia Therapeutics Appoints Luca Scavo as CFO and James Priour as Chief Product Officer - citybiz

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	19 (M)
Shares Float	17 (M)
Held by Insiders	0.1 (%)
Held by Institutions	12.8 (%)
Shares Short	197 (K)
Shares Short P.Month	156 (K)

EPS	-15.65
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.42
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-83.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.68
Qtrly Earnings Growth	0 %
Operating Cash Flow	-74 (M)
Levered Free Cash Flow	-43 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	-0.01
Price to Sales	0
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.